A phase I/ II study of brentuximab vedotin + AVD in paediatric patients with advanced Hodgkin lymphoma
Year: 2025
Type: article
Abstract: Prior Presentation: Franklin ARK, et al.Oral 037: An open-label, phase 1/2 study of front-line brentuximab vedotin + adriamycin, vinblastine and dacarbazine in paediatric patients with advanced-stage Hodgkin lymphoma.Presented at the 16th International Conference of Malignant Lymphoma (16-ICML Virtual Edition).18-22 June 2021.Lugano, Switzerland.Franklin ARK, et al.Oral 10,000: Updated safety and efficacy data from an open-label, phase 1/2 study of front-line brentuximab vedotin plus doxorubicin, vinblastine and dacarbazine (A + AVD) in paediatric patients with advanced-stage classical Hodgkin lymphoma (cHL).Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.3-7 June 2022.Chicago, IL.Locatelli, F et al.P1088: Updated data from a phase 1/2 study of brentuximab vedotin combined with chemotherapy in paediatric patients with advanced-stage classical Hodgkin lymphoma.Presented at the European Hematology Association (EHA) hybrid congress.
Source: British Journal of Haematology
DOI: 10.1111/bjh.70207
Institutions: Universidade Federal da Bahia, Hospital São Rafael, Support group for adolescents and children with cancer, Universidade Federal de São Paulo, Hospital Erasto Gaertner, Ospedale Regina Margherita, University of Turin, Hospital Santa Marcelina, Instituto Nacional de Câncer - INCA, Universidade de São Paulo, Policlinico San Matteo Fondazione, Meyer Children's Hospital, Sapporo Hokuyu Hospital, Kyushu University, Università Cattolica del Sacro Cuore, Bambino Gesù Children's Hospital
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W4415148408